Stemedica
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions.
Team
Stemedica has a team of experienced scientists, management and technicians to progress our proprietary technology.
Technology
Stemedica’s proprietary platform technology produces multiple progenitor cell products that meet exacting quality standards required for a cGMP licensed facility.
Trials
Stemedica is currently advancing clinical trials in the United States for several critical medical conditions.
Latest News
FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica’s itMSC Therapy for COVID-19 Patients
SAN DIEGO, Calif. — September 28, 2020 — Stemedica Cell Technologies, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for "A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the...
Stemedica in the News! ProMedica Researchers Observe Encouraging Outcomes with Use of Allogeneic Stem Cells in COVID-19 Patients
TOLEDO, Ohio, July 28, 2020 – ProMedica today announced the promising results of its new study that evaluated the use of stem cells in the treatment of adult COVID-19 patients. Eight patients elected to participate in a study under Emergency Investigational New Drug...
FIRST COVID-19 PATIENT TREATED UNDER EMERGENCY USE IND AT PROVIDENCE SAINT JOHN’S HEALTH CENTER USING STEMEDICA ISCHEMIA-TOLERANT ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
SANTA MONICA – April 20, 2020 – A single patient, emergency Investigational New Drug (IND) use was cleared by the U.S. Food and Drug Administration for the treatment of severe lung injury due to COVID-19 at the Providence Saint John’s Health Center, Santa Monica,...